The use of caspofungin in HIV-infected individuals

Expert Opinion on Investigational Drugs

Volumn 16, Issue 6, 2007, Pages 899-908

  Waters, Laura ^a   Nelson, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antifungal; Caspofungin; Echinocandin; HIV; Opportunistic infection

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN PLUS FLUCONAZOLE; ANTIRETROVIRUS AGENT; CANDIDAS; CARBAMAZEPINE; CASPOFUNGIN; CASPOFUNGIN PLUS VORICONAZOLE; CREATININE; CYCLOSPORIN A; DEXAMETHASONE; EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LIVER ENZYME; MICAFUNGIN; NEVIRAPINE; PHENYTOIN; PLACEBO; POSACONAZOLE; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RIFAMPICIN; SULFAMETHOXAZOLE; TACROLIMUS; TRIAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; AIDS RELATED COMPLEX; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; BRONCHOSPASM; CANDIDA MENINGITIS; CANDIDEMIA; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; LIVER TOXICITY; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; OROPHARYNX CANDIDIASIS; PHLEBITIS; PNEUMOCYSTIS PNEUMONIA; PRURITUS; RASH; SIDE EFFECT; THROMBOPHLEBITIS; THRUSH; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; PEPTIDES, CYCLIC;

EID: 34250003470     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.6.899     Document Type: Article

References (88)

1. LUNDGREN JD, MOCROFT A: The impact of antiretroviral therapy on AIDS and survival. J. HIV Ther. (2006) 11(2):36-38.
2. SABIN C, SMITH C, GUMLAY H et al.: Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS (2004) 18(16):2145-2151.
3. MCCARTHY K, MORGAN J, WANNEMUEHLER K et al.: Population-based surveillance for cryptococcosis in an antiretroviral-naïve South African province with a high seroprevalence. AIDS (2006) 20:2199-2206.
4. Caspofungin: L-743,872, MK 0991, MK 99 1. Drugs R&D (1999) 1:165-167.
5. HALL GS, MYLES C, PRATT KJ, WASHINGTON JA: Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis. Antimicrob. Agents Chemother. (1988) 32:1331-1335.
6. BALKOVEC JM, BLACK RM, ABRUZZO GK, BARTIZAL K, DREIKORN S, NOLLSTADT K: Pneumocandin antifungal lipopeptides. The phenolic hydroxyl is required for 1,3-β-D-glucan synthesis inhibition. Bioorg. Med. Chem. Lett. (1993) 3:2039-2042.
7. KURTZ MB, HEATH IB, MARRINAN J, DREIKORN S, ONISHI J, DOUGLAS C: Morphological effects of lipopeptides against Aspergillus fumigatus correlates with activity against (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. (1994) 38:1480-1489.
8. POWLES MA, LIBERATOR P, ANDERSON J et al.: Efficacy of MK-0991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother. (1998) 42:1985-1989.
9. BILLS G F, PLATAS G, PELÁEZ F, MAZUREKAR P: Reclassification of a pneumocandin-producing anamorph, Glarea lozoyensis, gen et sp. nov., previously identified as Zakrion arboricola. Mycol. Res. (1998) 103:179-192.
10. STONE JA, HOLLAND SD, WICKERSHAM PJ et al: Single- and multiple-dose pharmacokinetics; of caspofungin in healthy men. Antimicrob. Agents Chemother. (2002) 46(3):739-745.
11. MERCK SHARP & DOHME LTD: Cancidas® (caspofiingin powder for concentrate for solution for infusion). Summary of Product Characteristics. Merck Sharp & Dohme Ltd, Whitehouse Station, USA (October 2004).
12. BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41:2326-2332.
13. BARTIZAL C, ODDS FC: Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob. Agents Chemother. (2003) 47(7):2100-2107.
14. JOHNSON MD, PERFECT JR: Caspofungin: first approved agent in a new class of antifungals. Expert Opin. Pharmacother. (2003) 4(5):807-823.
15. CUENCA-ESTRELLA M, GOMEZ-LOPEZ A, GARCIA-EFFRON G et al.: Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother. (2005) 49(3):1232-1235.
16. SANER F, GENSICKE J, RATH P et al.: Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection (2006) 34(6):328-332.
17. STONE JA, MIGOYA EM, HICKEY L et al.: Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. (2004) 48(11):4306-4314.
18. Cancidas® Prescribing Information, Merck & Co. (February 2005).
19. ARATHOON EG, GOTUZZO E, NORIEGA LM, BERMAN RS, DINUBILE MJ, SABLE CA: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. (2002) 46(2):451-457.
20. VILLANUEVA A, ARATHOON EG, GOTUZZO E, BERMAN RS, DINUBILE MJ, SABLE CA: A randomized double-blind study of caspofungin versus amphotericin for the treatment of Candidal esophagitis. Clin. Infect. Dis. (2001) 33(9):1529-1535.
21. NELSON PW, LOZANO-CHIU M, REX JH: In vitro growth-inhibitory activity of pneumoncandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions. J. Med. Vet. Mycol. (1997) 35:285-287.
22. PEALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. (1998) 30:251-255.
23. MARCO F, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. (1998) 32:33-37.
24. VAZQUEZ JA, LYNCH M, BOIKOV D, SOBEL JD: In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. (1997) 41:1612-1614.
25. PARK S, KELLY R, NIELSEN KAHN J et al.: Specific sucstitutions in the echinocandin target Fks1p accoutn for reduced susceptibility of rare laboratory and clinical Candida species isolates. Antimicrob. Agents Chemother. (2005) 49(8):3264-3273.
26. BALASHOV SV, PARK S, PERLIN DS: Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. (2006) 50(6):2058-2063.
27. ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. (2001) 45:327-330.
28. FRANZOT SP, CASADEVALL A: Pneumoncandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. (1997) 41:331-336.
29. CUENCA-ESTRELLA M, GOMEZ-LOPEZ A, MELLADO E, BUITRAGO MJ, MONZON A, RODRIGUEZ-TUDELA JL: Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. (2006) 50(3):917-921.
30. ARAUJO R, PINA-VAZ C, RODRIGUES AG: Susceptibility of environmental versus clinical strains of pathogenic Aspergillus. Int. J Antimicrob. Agents (2007) 29(l):108-111.
31. HOWARD SJ, WEBSTER I, MOORE CB et al.: Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents (2006) 28(5):450-453.
32. MILLER CD, LOMAESTRO BW, PARK S, PERLIN DS: Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy (2006) 26(6):877-880.
33. HERNANDEZ S, LOPEZ-RIBOT JL, NAJVAR LK, MCCARTHY DI, BOCANEGRA R, GRAYBILL JR: Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. (2004) 48(4):1382-1383.
34. ELOY O, BLANC V, PINA P et al.: Epidemiology of candidernia: results of a one month French hospitals-based surveillance study in 2004. Pathol. Biol. (Paris) (2006) 54(8-9):523-530.
35. ARENDRUP MC, FUURSTED K, GAHRN-HANSEN B et al.: Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J. Clin. Microbiol. (2005) 43(9):4434-4440.
36. PFALLER MA, BOYKEN L, HOLLIS RJ, MESSER SA, TENDOLKAR S, DIEKEMA DJ: Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofiingin by CLSI-recommended methods. J. Clin. Microbiol. (2006) 44(10):3533-3538.
37. GOTTLIEB MS, SCHROFF R, SCHANKER HM et al.: Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence for a new acquired cellualr immunodeficiency. N. Engl. J. Med. (1981) 305:1425-1431.
38. MOORE RD, CHAISSON RE: Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann. Intern. Med. (1996) 124:633-642.
39. CAUDA R, TACCONELLI E, TUMBARELLO et al.: Role of protease inhibitors in preventing recurent oral candiosis in patients with HIV infection: a prospective case-control study. J. Acquir. Immune Defic. Syndr. (1999) 21:20-25.
40. SCHMIDT-WESTHAUSEN AM, BENDICK C, REICHART PA, SAMARANAYAKE LP: Oral candidosis and associated Candida species in HIV-infected Cambodians exposed to antimycotics. Mycoses (2004) 47:435-441.
41. SCHORLING SR, KORTINGA HC, FROSCHB M, MUHLSCHLEGEL FA: The role of Candida dubliniensis in oral candidiasis in human immunodeficiency-infected individuals. Crit. Rev. Microbiol. (2000) 26:59-68.
42. JABRA-RIZK MA, FALKLER WA Jr, MERZ WG, BAQUI AA, KELLEY JI, MEILLER TF: Retrospective identification and characterisation of Candida dubliniensis isolates among Candida albicans clinical laboratory isolatesfrom human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals. J. Clin. Microbiol. (2000) 38:2423-2426.
43. FICHTENBAUM CJ, KOLETAR S, YIANNOUTSOS C et al.: Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin. Infect. Dis. (2000) 30:749-756.
44. MARTINS MD, LOZANO-CHIU M, REX JH: Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin. Infect. Dis. (1998) 27:1291-1294.
45. POWDERLYWG, ROBINSON K, KEATH EJ: Molecular typing of Candida albicans isolated form oral lesions of HIV-infected individuals. AIDS (1992) 6:81-84.
46. REX JH, PFALLER MA, GALGIANI JN et al.: Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin. Infect. Dis. (1997) 24(2):235-247.
47. ST-GERMAIN G, DION C, ESPINEL-INGROFF A, RATELLEJ, DE REPENTIGNY L: Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV. J. Antimicrob. Chemother. (1995) 36(l):109-118.
48. LAGUNA F, RODRIGUEZ-TUDELA JL, MARTINEZ-SÚAREZ JV et al.: Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin. Infect. Dis. (1997) 24(2):124-130.
49. HE X, TIBALLI RN, ZARINS LT, BRADLEY SF, SANGEORZAN JA, KAUFFMAN CA: Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. (1994) 38(10):2495-2497.
50. DE REPENTIGNY L, RATELLE J: Comparison of itraconazole and ketoconazole in HIV-positive patients wit oropharyngeal or esophageal candidiasis. Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group. Chemotherapy (1996) 42(5):374-383.
51. LAINE L, DRETLER RH, CONTEAS CN et al.: Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann. Intern. Med. (1992) 117(8):655-660.
52. ALLY R, SCHURMANN D, KREISEL W et al.: A randomized double-blind, double-dummy, multicenter trial of voriconzote and fluconazole for the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. (2001) 33:1447-1454.
53. VAZQUEZ JA, SKIEST DJ, NIETO L et al.: A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect, Dis. (2006) 42(8):1179-1186.
54. KARTSONIS NA, SAAH A, LIPKA CJ, TAYLOR A, SABLE CA: Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. J. Antimicrob. Chemother. (2004) 53:878-881.
55. VILLANUEVA A, GOTUZZO E, ARATHOON EG et al.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. (2002) 113(4):294-299.
56. DE WET N, LLANOS-CUENTAS A, SULEIMAN Y et al.; A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. (2004) 39:842-849.
57. MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347(25):2020-2029.
58. DINUBILE MJ, LUPINACCI RJ, BERMAN RS, SABLE CA: Response and relapse rates of Candidal esophagitis in HIV-infected patients treated with caspofungin. AIDS Res. Hum. Retroviruses (2002) 18(13):903-908.
59. KARTSONIS N, DINUBILE MJ, BARTIZAL K et al..: Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J. Acquir. Immune Defic. (2002) 31:183-187.
60. ZAAS AK, DODDS ASHELT ES, ALEXANDER BD, JOHNSON MD, PERFECT JR: Caspofungin for invasive candidiasis at a tertiary care medical centre. Am. J. Med. (2006) 119(11):el-e6.
61. HOSSAIN MA, REYES GH, LONG LA, MUKHERJEE PK, GHANNOUM MA: Efficacy of caspofilngin combined with amphotericin B against azole-resistant Candida albicans. J. Antimicrob. Chemother. (2003) 51(6):1427-1429.
62. OLVER WJ, SCOTT E, SHANKLAND GS: Successful treatment of candidi krusei fungemia with amphotericin B and caspofungin. Med. Mycol. (2006) 44(7):655-657.
63. BACAK V, BIOCINA B, STARCEVIC B, GERTLER S, BEGOVAC J: Candida albicans endocarditis treatment with caspoftingin in an HIV-infected patient-case report and review of literature. J. Infect. (2006) 53(l):ell-el4.
64. LEGOUT L, ASSAL M, ROHNER P, LEW D, BERNARD L, HOFFMEYER P: Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient. Scand. J. Infect. Dis. (2006) 38(8):728-730.
65. LIU KH, WU CJ, CHOU CH et al.: Refractory Candidal meningitis in an immunocompromised patient cured by caspofungin. J. Clin. Microbiol. (2004) 42(12):5950-3
66. KHOO SH, DENNING DW: Invasive aspergillosis in patients with AIDS. Clin. Infect. Dis. (1994) 19(Sl):S41-S48.
67. MINAMATO GY. BARLAM TF, VANDER ELS NJ: Invasive aspergillosis in patients with AIDS. Clin. Infect. Dis. (1992) 14:66-74.
68. HOLDING KJ, DWORKIN MS, WAN PC et al.: Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clin. Infect. Dis. (2000) 31:1253-1257.
69. MORENO A, PEREX-ELIAS M, CASADO J et al.: Role of antiretroviral therapy in long-cerm survival of patients with AIDS-related pulmonary aspergillosis. Eur. J. Clin. Microbiol. Infect. Dis. (2000) 19:688-693.
70. DENNING DW, FOLLANSBEE SE, SCOLARO M, NORRIS S, EDELSTEIN H STEVENS DA: Pulmonary aspergillosis in the aquired immunodeficiency syndrome. N. Engl. J. Med. (1991) 324:654-662.
71. MOSQUERA J, SHARP A, MOORE CB, WARN PA, DENNING DW: In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J. Antimicrob. Chemother. (2002) 50:189-194.
72. DENNING DW, MARINUS A, COHEN J et al.: An EORTC multicentre prospective survey of invasive aspergillosis in haernatological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J. Infect. (1998) 37(2):173-180.
73. DENNING DW. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. (1996) 23(3):608-615.
74. GROLL AH, WALSH TJ: Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs (2001) 10(8):1545-1558.
75. SABLE CA, NGUYEN BY, CHODAKEWITZ JA, DINUBILE MJ: Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl. Infect. Dis. (2002) 4:25-30.
76. YEKUTIEL A, SHALIT I, SHADKCHAN Y. OSHEROV N: In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Cbemother. (2004) 48(9):3279-3283.
77. MAERTENS J, GLASMACHER A, HERBRECHT R et al..: Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer (2006) 107(12):2888-2897.
78. MARR KA, BOECKH M, CARTER RA, KIM HW, COREY L: Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. (2004) 39(6):797-802.
79. ALIOGLU B, AVCI Z, CANAN O, OZCAY F, DEMIRHAN B, OZBEK N: Invasive esophageal aspergillosis associated with acute myelogenous leukemia: successful therapy with combination caspofungin and liposomal amphotericin B. Pediatr. Hematol. Oncol. (2007) 24(l):63-68.
80. DENNING DW, LEE JY, HOSTETLER JS et al.: NIAID Mycoses Study Group. Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am. J. Med. (1994) 97:135-144.
81. STRINGER JR, BEARD CB, MILLER RF, WAKEFIELD AE: A new name ( Pneumocystis jiroveci) for pneurnocystis in humans. Emerg. Infect. Dis. (2002) 8(9):891-896.
82. POWLES MA, ANDERSON J, LIBERATORP et al.: Efficacy of semisynthetic pneurnocandin analog L-743,872 against Pneumocystis carinii in murine models. 36th ICAAC. San Diego, USA(1996): F42(Abstract).
83. ITO M, NOZU R, KURAMOCHI T et al.: Prophylactic effect of FK463, anovel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob. Agents Chemother. (2000) 44(9):2259-2262.
84. PATEL N, KOZIEL H: Pneumocystis pneumonia in adult patients with AIDS. Treatment strategies and emerging challenges to antimicrobial therapy. Treat. Respir. Med.(2004)3(6):381-397.
85. WATERS L, DARLING K, MIN J, BOWER M, GAZZARD B, NELSON M: Caspofungin in the treatment of severe Pneumocystis jiroveci pneumonia (PCP). HIV Med.(2006)7(Sl):22 (AbstractP47).
86. BELTZ K, KRAMMC M, LAWS H-J, SCHROTEN H, WESALOWSKI R, GOBEL U: Combined trimethoprim and caspohingin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukaernia. Min. Padiatr. (2006) 218(3):177-179,
87. KAMBOJ M, WEINSTOCK D, SEPKOWITZ KA: Progression of Pneumocystis Jiroveci pneumonia in patients receving echinocandin therapy. Clin. Infect. Dis. (2006)43(9):02-04.
88. ZHANG JC, DAI JY, FAN J, WUX P: The treatment of Pneumocystis carinii pneumonia with caspofungin in elderly patients: a case report and literature review. Zhonghus Jie He He Hu Xi Za Zhi (2006) 29(7):463-465.